Search

everythinglearnresearchcommunity

for

Search:↓

Androgenetic alopecia is linked to higher cardiovascular and metabolic risks, possibly due to irisin resistance.

Low HDL-C, uric acid, and 25-hydroxyvitamin D are risk factors for early-onset male hair loss.

People with alopecia areata have higher levels of a heart disease marker than those without hair loss.

Hair loss can indicate brain aging and potential small vessel disease, but more research is needed to understand the clinical impact.

The document concludes that diagnosing PCOS requires a thorough approach, considering various symptoms and risks, and calls for improved methods to identify PCOS types and prevent diabetes.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

The conclusion is that managing cholesterol is important for women, especially during pregnancy, breastfeeding, and with PCOS, and involves regular screening and careful treatment choices.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

Women with PCOS who have low SHBG are more likely to have low good cholesterol and metabolic syndrome.

The Rotterdam Study found risk factors for elderly diseases, links between lifestyle and genetics with health conditions, and aimed to explore new areas like DNA methylation and sensory input effects on brain function.

Low IGF-1 and high HDL cholesterol levels are linked to more hair loss in middle-aged women.

Polycystic Ovary Syndrome is linked to higher risk of hypertension and heart disease.

The document concludes that hormonal biomarkers are key for diagnosing hyperandrogenemia in women and hypogonadism in men.

The document concludes that effectively managing PCOS requires a multifaceted approach.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Androgenetic alopecia is a common hair loss condition influenced by various factors and linked to psychosocial and cardiovascular issues.

MicroRNAs could be key biomarkers and therapeutic targets for PCOS.

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.

Women with non-classic congenital adrenal hyperplasia have higher risk for heart and metabolic problems.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

People with PCOS, especially if obese, often have NAFLD, linked to obesity, insulin resistance, and high androgen levels.

Male-pattern hair loss is largely influenced by genetics, with key genes identified.

Hair loss in young men linked to higher risk of insulin resistance and metabolic issues.

Women with PCOS are at higher risk for gum disease, and managing shared risk factors can help both conditions.

Androgenetic alopecia is linked to a higher risk of coronary heart disease due to certain genetic factors and high homocysteine levels.

Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.

Women with PCOS in North China often have hirsutism and acne, with hirsutism linked to metabolic issues.

High androgen levels in postmenopausal women may suggest an ovarian tumor, and removing it can improve heart and metabolic health.

Women with PCOS are more than twice as likely to develop nonalcoholic fatty liver disease.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.